Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives
- PMID: 11028571
- DOI: 10.1111/j.1471-0528.2000.tb11610.x
Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives
Abstract
Objective: To assess the relative contraceptive effectiveness, tolerability and acceptability of the levonorgestrel-releasing (20 microg per day) intrauterine system (LNG-20) compared with reversible contraceptive methods in women of reproductive age.
Design: A systematic review and meta-analysis of randomised controlled trials.
Identification: Studies were identified through seven databases, and by contacting investigators and organisations working in the contraceptive field.
Main outcome measures: Unplanned pregnancy and continuation of contraceptive method.
Results: Five of the seven randomised controlled trials which met the inclusion criteria were included in the meta-analyses; four were comparisons of the LNG-20 intrauterine system with nonhormonal intrauterine devices. LNG-20 intrauterine systems were compared with intrauterine devices divided into two categories, those > 250 mm3 (Copper T 380 Ag and Copper T 380A intrauterine devices) and those < or = 250 mm3 (Nova-T, Copper T 220C and Copper 200 intrauterine devices). Pregnancy rates for the LNG-20 intrauterine system users were significantly less likely to become pregnant compared with users of intrauterine devices < or = 250 mm3, and significantly less likely to have an ectopic pregnancy. LNG-20 intrauterine system users were more likely to experience amenorrhoea and device expulsion than women using intrauterine devices > 250 mm3. LNG-20 intrauterine system users were significantly more likely than all the intrauterine device users to discontinue because of hormonal side effects and amenorrhoea. When the LNG-20 intrauterine system was compared with Norplant-2, the LNG-20 users were significantly more likely to experience oligo-amenorrhoea, but significantly less likely to experience prolonged bleeding and spotting.
Conclusions: The effectiveness of the LNG-20 intrauterine system was similar to or better than other contraceptive methods with which it was compared. Amenorrhoea was the main reason for the discontinuation of the LNG-20 intrauterine system, usually unnecessarily, since this end-organ suppression of bleeding is benign, associated with normal oestrogen levels. Women choosing this method should be informed of potential amenorrhoea when having pre-contraceptive counselling and that absent bleeding may be viewed as a positive outcome.
Comment in
- ACP J Club. 2001 Sep-Oct;135(2):64
-
Levonorgestrel-releasing (20mcg/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives.BJOG. 2001 Jul;108(7):770-1. doi: 10.1111/j.1471-0528.2001.00157.x. BJOG. 2001. PMID: 11467711 No abstract available.
Similar articles
-
Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.Cochrane Database Syst Rev. 2004;2004(3):CD001776. doi: 10.1002/14651858.CD001776.pub2. Cochrane Database Syst Rev. 2004. PMID: 15266453 Free PMC article.
-
Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.Cochrane Database Syst Rev. 2001;(2):CD001776. doi: 10.1002/14651858.CD001776. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2004;(3):CD001776. doi: 10.1002/14651858.CD001776.pub2. PMID: 11406007 Updated.
-
Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002126. doi: 10.1002/14651858.CD002126.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2015 Apr 30;(4):CD002126. doi: 10.1002/14651858.CD002126.pub3. PMID: 16235297 Updated.
-
Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding.Cochrane Database Syst Rev. 2000;(2):CD002126. doi: 10.1002/14651858.CD002126. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002126. doi: 10.1002/14651858.CD002126.pub2. PMID: 10796865 Updated.
-
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007245. doi: 10.1002/14651858.CD007245.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2015 Dec 09;(12):CD007245. doi: 10.1002/14651858.CD007245.pub3. PMID: 19821400 Updated.
Cited by
-
Role of the levonorgestrel intrauterine system in effective contraception.Patient Prefer Adherence. 2013 Aug 9;7:777-85. doi: 10.2147/PPA.S36948. eCollection 2013. Patient Prefer Adherence. 2013. PMID: 23990713 Free PMC article.
-
Reproductive Planning and the Choice of Long-acting Reversible Contraceptive Primary to Health: A Cross-Sectional Study.Rev Bras Ginecol Obstet. 2023 Aug;45(8):e456-e464. doi: 10.1055/s-0043-1772188. Epub 2023 Sep 8. Rev Bras Ginecol Obstet. 2023. PMID: 37683657 Free PMC article.
-
Different bleeding patterns with the use of levonorgestrel intrauterine system: are they associated with changes in uterine artery blood flow?Biomed Res Int. 2014;2014:815127. doi: 10.1155/2014/815127. Epub 2014 Apr 23. Biomed Res Int. 2014. PMID: 24868549 Free PMC article.
-
Gynaecological health in adult congenital heart disease women: Addressing menorrhagia, infertility, contraception, menopause.Int J Cardiol Congenit Heart Dis. 2023 Aug 2;13:100470. doi: 10.1016/j.ijcchd.2023.100470. eCollection 2023 Sep. Int J Cardiol Congenit Heart Dis. 2023. PMID: 39712231 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous